Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Using index level provides a macro view of market direction, helping you balance stock-specific decisions with overall sentiment.
27,685 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Altria sits around $73 with a near-6% yield, yet a from 52-week low: glaring risk and consumer softness raise questio...
NVIDIA is at the center of the AI hardware boom, fueling bets that the stock will climb to new highs by 2027. Analyst...
After a quarterly report, Netflix's post-earnings sell-off just highlighted a shift in strategy. This article breaks ...
Nvidia faces a pivotal test in 2029 as AI demand continues to power growth, but regulatory hurdles and supply constra...
A hypothetical $10,000 Exxon investment at the outbreak of the Iran conflict has produced a mixed bag of results. Her...
As pepsico (pep) 2026 earnings shape the near-term outlook, investors want clarity on growth drivers, costs, and capi...
A clear guide to the latest ANIP quarterly update. We unpack the numbers, translate management commentary into real-w...
Investors eye Hewlett Packard Enterprise’s 2026 earnings call for guidance on AI demand, GreenLake growth, and capita...
When a tech titan backs a biotech startup, investors take note. This article digs into whether Jeff Bezos backed Grai...
RunSybil secures $40 million in a funding round led by Khosla Ventures, backing its autonomous AI agents that hack li...
AI-driven research is producing fake references at scale, threatening the reliability of published knowledge. The fal...